Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 484-490

  Georgiou, Niki A ^a   Van Der Bruggen, Tjomme ^b   Oudshoorn, Maroeska ^a   Nottet, Hans S L M ^b   Marx, Joannes J M ^a,b   Van Asbeck, B Sweder ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BLEOMYCIN; DEFERIPRONE; DEFEROXAMINE; DIDANOSINE; IRON CHELATING AGENT;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; BLEOMYCIN; CYTOTOXICITY, IMMUNOLOGIC; DEFEROXAMINE; DIDANOSINE; DRUG SYNERGISM; HIV CORE PROTEIN P24; HIV-1; HUMANS; IRON CHELATING AGENTS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MACROPHAGES; MONOCYTES; PYRIDONES; VIRUS REPLICATION;

EID: 0034006433     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315223     Document Type: Article

References (46)

1. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T-cells. Nature 1987;326:711-3.
2. Sappey C, Boelaert JR, Legrand Poels S, Forceille C, Favier A, Piette J. Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res Hum Retroviruses 1995;11:1049-61.
3. Lee R, Beauparlant P, Elford H, Ponka P, Hiscott J. Selective inhibition of I kappaB alpha phosphorylation and HIV-1 LTR-directed gene expression by novel antioxidant compounds. Virology 1997;234:277-90.
4. Tabor E, Epstein JS, Hewlett IK, Lee SF. Inhibition by desferrioxamine of in-vitro replication of HIV-1. Lancet 1991;337:795.
5. Lazdins JK, Alteri E, Klimkait T, et al. Lack of effect of desferrioxamine on in-vitro HIV-1 replication. Lancet 1991;338:1341-2.
6. Hoffbrand AV, Ganeshaguru K, Hooton JWL, Tattersall MHN. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976;33:517-26.
7. Brown NC, Aliasson R, Reichard P, Thelander L. Spectrum and iron content of protein B2 from ribonucleotide diphosphate reductase. Eur J Biochem 1969;9:512-8.
8. Moore EC, Zodeck MS, Argawal KC, Sartorelli AC. Inhibition of ribonucleoside diphosphate reductase by 1-formylisoquinoline thiosemicarbazone and related compounds. Biochemistry 1970;9:4492-8.
9. Hoyes KP, Porter JB. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 1993;85:393-400.
10. Nyholm S, Mann GJ, Johansson AG, Bergeron RJ, Graslund A, Thelander L. Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem 1993;268:26200-5.
11. Lederman HM, Cohen A, Lee JWW, Freedman MH, Gelfand EW. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984;64:748-53.
12. Umezawa H, Maeda K, Takeuchi T, Okama Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 1966;19:200-9.
13. Comis RL. Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol 1992;19(Suppl 5):64-70.
14. Povrik LF, Hogan M, Dattagupta N. Binding of bleomycin to DNA: intercalation of the bithiazole rings. Biochemistry 1979;18:96-101.
15. Carter BJ, de Vroom E, Long EC, van der Marel GA, van Boom JH, Hecht SM. Site-specific cleavage of RNA by Fe(II) bleomycin. Proc Natl Acad Sci USA 1990;87:9373-7.
16. Holmes CE, Carter BJ, Hecht SM. Characterization of iron(II)·bleomycin-mediated RNA strand scission. Biochemistry 1993;32:4293-307.
17. Lown J, Sim S. The mechanism of the bleomycin-induced cleavage of DNA. Biochem Biophys Res Commun 1977;77:1150-7.
18. Sausville E, Peisach J, Horwitz S. A role for ferrous ion and oxygen in the degradation of DNA by bleomycin. Biochem Biophys Res Commun 1976;73:814-22.
19. Hecht SM. RNA degradation by bleomycin, a naturally occurring bioconjugate. Bioconjug Chem 1994;5:513-26.
20. Gerrard TL, Jurgensen CH, Fauci AS. Differential effect of monoclonal anti-DR antibody on monocytes in antigen- and mitogen-stimulated responses: mechanism of inhibition and relationship to interleukin-1 secretion. Cell Immunol 1983;82:394-402.
21. Gruber MF, Weih KA, Boone EJ, Smith PD, Clouse KA. Endogenous macrophage CSF production is associated with viral replication in HIV-1-infected human monocyte-derived macrophages. J Immunol 1995;154:5528-35.
22. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990;250:1139-42.
23. McKeating JA, McKnight A, Moore JP. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects of infectivity and neutralization. J Virol 1991;65:852-60.
24. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-21.
25. Chou TC, Hayball MP. CalcuSyn: Windows software for dose effect analysis. Cambridge, UK: Biosoft, 1996.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
27. Pattanapanyasat K, Webster HK, Tongtawe P, Kongcharoen P, Hider RC. Effect of orally active hydroxypyridone iron chelators on human lymphocyte function. Br J Haematol 1992;82:13-9.
28. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen ISY. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990;61:213-22.
29. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8.
30. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-5.
31. Vila J, Biron F, Nugier F, Vallet T, Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection [letter]. Lancet 1996;348:203-4.
32. Vila J, Nugier F, Bargues G, et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide [letter]. Lancet 1997;350:635-6.
33. Lori F, Jessen H, Foli A, Lisziewicz J, Matteo PS. Long-term suppression of HIV-1 by hydroxyurea and didanosine [letter]. JAMA 1997;277:1437-8.
34. De Boer RJ, Boucher CA. Anti-CD4 therapy for AIDS suggested by mathematical models. Proc R Soc Lond B Biol Sci 1996;263:899-905.
35. De Boer RJ, Boucher CA, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-70.
36. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S. Design of orally active iron chelators. Acta Haematol 1996;95:6-12.
37. Cragg L, Hebbel RP, Miller W, Solovey A, Selby S, Enright H. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 1998;92:632-8.
38. Porter JB, Gyparaki M, Burke LC, Huehns ER, Hider RC, Saez V. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood 1988;72:1497-503.
39. Filderman AE, Genovese LA, Lazo JS. Alterations in pulmonary protective enzymes following systemic bleomycin treatment in mice. Biochem Pharmacol 1988;37:1111-6.
40. Scheule RK, Perkins RC, Hamilton R, Holian A. Bleomycin stimulation of cytokine secretion by the human alveolar macrophage. Am J Physiol 1992;262:L386-91.
41. Blum RH, Carter SK, Agre K. A clinical review of bleomycin a new antineoplastic agent. Cancer 1973;31:903-14.
42. Summers MR, Jacobs A, Tudway D, Perera P, Rickets C. Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br J Haematol 1979;42:547-55.
43. Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clin Pharmacol Ther 1990;48:255-61.
44. Olivieri NF, Koren G, Hermann C, et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-9.
45. al Refaie FN, Sheppard LN, Nortey P, Wonke B, Hoffbrand AV. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995;89:403-8.
46. Oken MM, Crooke ST, Elson MK, Strong JE, Shafer RB. Pharmacokinetics of bleomycin after IM administration in man. Cancer Treat Rep 1981;65:485-9.